Budd-Chiari syndrome and TIPS - 21 years' experience
Requires Subscription PDF

Keywords

portal hypertension
adult
child
lidé
lidé středního věku
mladiství
mužské pohlaví
postoperative complications
prospektivní studie
staří
staří nad 80 let
statistika jako téma
transjugulární intrahepatální portosystémový zkrat
výsledek terapie
ženské pohlaví
biokompatibilní potahované materiály
Buddův-Chiariho syndrom
dítě
Kaplanův-Meierův odhad
mladý dospělý
myeloproliferativní poruchy
polytetrafluoroethylen
portální hypertenze
stenty
terapie opakovaná
trombofilie
žilní trombóza

Abstract

Budd-Chiari syndrome (BCS) often has an acute or fulminant course leading to ischaemia and necrosis of the liver parenchyma as consequence of venostasis. Restitution of blood drainage is then a key measure. In the chronic course, symptoms of portal hypertension are dominant. TIPS as a portosystemic shunt ensures both venous drainage as well as corrected portal hypertension.

Patients and methods: TIPS has already been available for 21 years in the Czech Republic. Using this method we also treated 52 patients with BCS from thrombosis of hepatic veins. The median age was 37 years (13 to 82 years), 10% were children, 16 patients (31%) were men, 31% procedures were urgent. Myeloproliferative syndrome was the cause in 60%, another thrombophilic disorder was detected in 15%, and in 25% of them the cause was not elucidated. In the first five years, uncovered stents were used, but since 1997 different types of ePTFE covered stents have been available and since 2001 dedicated ePTFE covered stents became the standard.

Results: 13 patients died: three of fulminant liver failure, one of extensive tumorous thrombosis, three of early septic complications, two of liver failure due to later acute shunt occlusion, two of progressions of haemato-oncological disease, one tragically, and one of unknown cause. Two patients later underwent OLTx. In 39 patients the shunt remains patent on anticoagulant therapy and occasional reinterventions, liver functions are stable and no portal hypertension complications occur. We have not noticed significant hepatic encephalopathy. The use of ePTFE covered stents reduced a number of mainly early occlusions. In imaging we often find nodular hyperplasia.

Conclusion: WeconsiderTIPS an advantageous therapeutic approach in BCS dueto thrombosis of the hepatic veins. If the follow-up treatment is rigorous, the TIPS usually ensures sufficient perfusion of the liver and prevents portal hypertension complications, saving most patients from livertransplantation.

External Links

Requires Subscription PDF